Food and Drug Administration (FDA) expanded Wegovys approved uses to include reducing the risk of cardiovascular death, heart attack, and stroke in adults who are obese, overweight, or have established cardiovascular disease
Important considerations include: Weight loss history Eating habits Cravings and appetite patterns Work and travel schedules Exercise routine Overall health goals Customized treatment plans often produce more sustainable long-term results than one-size-fits-all approaches
Two groups were matched for age, gender, comorbidities, and other soft tissue and inflammatory issues, HbA1c, sleep apne, BMI, opioid use, NSAID use, antidepressants
Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido
Peroxide mediated effects of homocysteine on arterial prostacyclin synthesis
medical providers for GLP-1 and GLP-1/GIP medications , including compounded tirzepatide